<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914303</url>
  </required_header>
  <id_info>
    <org_study_id>D0490C00002</org_study_id>
    <secondary_id>EudraCT No 2007-003145-33</secondary_id>
    <nct_id>NCT00914303</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241</brief_title>
  <official_title>A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the study are to assess the safety, tolerability and pharmacokinetics of ER
      tablets of AZD3241 following multiple ascending doses administered to healthy male and female
      subjects including the effect of food.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety variables (adverse events, vital signs, ECG, safety lab)</measure>
    <time_frame>Assessments performed at frequent timepoints during a 4-8 week period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of AZD3241 in plasma</measure>
    <time_frame>Frequent sampling occasions during some study days for a 4-8 weeks period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AZD3241</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3241 Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3241</intervention_name>
    <description>Oral Tablet, Repeated Administration</description>
    <arm_group_label>AZD3241</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Oral Tablet. Repeated Administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects 30-65 years

          -  Body Mass Index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more
             than 100 kg

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion of
             drugs

          -  Previous history of frequent pre-syncope or syncope
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Karlsten, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Science Director AstraZeneca R&amp;D Södertälje.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Kuhn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB Phase I Unit, Uppsala, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>April 5, 2010</last_update_submitted>
  <last_update_submitted_qc>April 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rolf Karlsten , MD, PhD, Medical Science Director</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>healthy</keyword>
  <keyword>Healthy volunteer study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

